The role of cilostazol, a phosphodiesterase 3 inhibitor, on oocyte maturation and subsequent pregnancy in mice

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Li, Min ^a,c   Yu, Yang ^a,c   Yan, Jie ^a,c   Yan, Li Ying ^a,b   Zhao, Yue ^a,b   Li, Rong ^a,c,d   Liu, Ping ^a,c   Hsueh, Aaron J ^b   Qiao, Jie ^a,c,d  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; CILOSTAZOL; 6 (5,6 DIMETHOXYBENZO[B]THIEN 2 YL) 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; CONTRACEPTIVE AGENT; PHOSPHODIESTERASE III INHIBITOR; TETRAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLASTOCYST; BLOOD PRESSURE MONITORING; BODY WEIGHT; CELL COUNT; CELL STRUCTURE; CELL VIABILITY; CHROMOSOME ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBRYO DEVELOPMENT; FEMALE; FERTILITY; FERTILIZATION; HEART RATE; IN VITRO STUDY; IN VIVO STUDY; INTERMITTENT CLAUDICATION; INTRACYTOPLASMIC SPERM INJECTION; MEIOSIS; MITOSIS SPINDLE; MOUSE; NONHUMAN; OOCYTE MATURATION; PREGNANCY; PROGENY; ANIMAL; ANIMAL EMBRYO; CELL CULTURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; EVALUATION; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; OOCYTE; OOCYTE DEVELOPMENT; PHYSIOLOGY;

MUS;

ANIMALS; CELLS, CULTURED; CONTRACEPTIVE AGENTS, FEMALE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EMBRYO, MAMMALIAN; FEMALE; FERTILIZATION; MALE; MEIOSIS; MICE; MICE, INBRED ICR; OOCYTES; OOGENESIS; PHOSPHODIESTERASE 3 INHIBITORS; PREGNANCY; TETRAZOLES; THIOPHENES;

EID: 84856207850     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030649     Document Type: Article

References (32)

1. Jensen JT, Speroff L, (2000) Health benefits of oral contraceptives. Obstetrics and Gynecology Clinics of North America 27 (4): 705-721.
2. Kaunitz AM, (1999) Oral contraceptive health benefits: perception versus reality. Contraception 59 (1 Suppl): 29S-33S.
3. Channing CP, Hillensjo T, Schaerf FW, (1978) Hormonal control of oocyte meiosis, ovulation and luteinization in mammals. Clinics in Endocrinology and Metabolism 7 (3): 601-624.
4. Richards JS, Hedin L, (1988) Molecular aspects of hormone action in ovarian follicular development, ovulation, and luteinization. Annual Review of Physiology 50: 441-463.
5. Tsafriri A, Chun SY, Zhang R, Hsueh AJ, Conti M, (1996) Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors. Developmental Biology 178 (2): 393-402.
6. Wiersma A, Hirsch B, Tsafriri A, Hanssen RG, Van de Kant M, et al. (1998) Phosphodiesterase 3 inhibitors suppress oocyte maturation and consequent pregnancy without affecting ovulation and cyclicity in rodents. The Journal of Clinical Investigation 102 (3): 532-537.
7. Nogueira D, Albano C, Adriaenssens T, Cortvrindt R, Bourgain C, et al. (2003) Human oocytes reversibly arrested in prophase I by phosphodiesterase type 3 inhibitor in vitro. Biology of Reproduction 69 (3): 1042-1052.
8. Jensen JT, Schwinof KM, Zelinski-Wooten MB, Conti M, DePaolo LV, et al. (2002) Phosphodiesterase 3 inhibitors selectively block the spontaneous resumption of meiosis by macaque oocytes in vitro. Human Reproduction (Oxford, England) 17 (8): 2079-2084.
9. Jensen JT, Zelinski-Wooten MB, Schwinof KM, Vance JE, Stouffer RL, (2005) The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation during gonadotropin-stimulated ovarian cycles in rhesus macaques. Contraception 71 (1): 68-73.
10. Jensen JT, Zelinski MB, Stanley JE, Fanton JW, Stouffer RL, (2008) The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation in the naturally selected dominant follicle in rhesus macaques. Contraception 77 (4): 303-307.
11. Jensen JT, Stouffer RL, Stanley JE, Zelinski MB, (2010) Evaluation of the phosphodiesterase 3 inhibitor ORG 9935 as a contraceptive in female macaques: initial trials. Contraception 81 (2): 165-171.
12. Kawamura K, Watanabe K, Kimura Y, (1985) Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Arzneimittel-Forschung 35 (7A): 1149-1154.
13. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr, (1998) Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98 (7): 678-686.
14. Soderling SH, Beavo JA, (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Current Opinion in Cell Biology 12 (2): 174-179.
15. Conti M, Andersen CB, Richard F, Mehats C, Chun SY, et al. (2002) Role of cyclic nucleotide signaling in oocyte maturation. Molecular and Cellular Endocrinology 187 (1-2): 153-159.
16. Sasseville M, Cote N, Guillemette C, Richard FJ, (2006) New insight into the role of phosphodiesterase 3A in porcine oocyte maturation. BMC Developmental Biology 6: 47.
17. Racowsky C, (1984) Effect of forskolin on the spontaneous maturation and cyclic AMP content of rat oocyte-cumulus complexes. Journal of Reproduction and Fertility 72 (1): 107-116.
18. Richard FJ, Tsafriri A, Conti M, (2001) Role of phosphodiesterase type 3A in rat oocyte maturation. Biology of Reproduction 65 (5): 1444-1451.
19. Thomas RE, Armstrong DT, Gilchrist RB, (2002) Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Developmental Biology 244 (2): 215-225.
20. Nogueira D, Cortvrindt R, De Matos DG, Vanhoutte L, Smitz J, (2003) Effect of phosphodiesterase type 3 inhibitor on developmental competence of immature mouse oocytes in vitro. Biology of Reproduction 69 (6): 2045-2052.
21. Thomas RE, Thompson JG, Armstrong DT, Gilchrist RB, (2004) Effect of specific phosphodiesterase isoenzyme inhibitors during in vitro maturation of bovine oocytes on meiotic and developmental capacity. Biology of Reproduction 71 (4): 1142-1149.
22. Liang CG, Huo LJ, Zhong ZS, Chen DY, Schatten H, et al. (2005) Cyclic adenosine 3′,5′-monophosphate-dependent activation of mitogen-activated protein kinase in cumulus cells is essential for germinal vesicle breakdown of porcine cumulus-enclosed oocytes. Endocrinology 146 (10): 4437-4444.
23. Vanhoutte L, De Sutter P, Nogueira D, Gerris J, Dhont M, et al. (2007) Nuclear and cytoplasmic maturation of in vitro matured human oocytes after temporary nuclear arrest by phosphodiesterase 3-inhibitor. Human Reproduction (Oxford, England) 22 (5): 1239-1246.
24. Shu YM, Zeng HT, Ren Z, Zhuang GL, Liang XY, et al. (2008) Effects of cilostamide and forskolin on the meiotic resumption and embryonic development of immature human oocytes. Human Reproduction (Oxford, England) 23 (3): 504-513.
25. Jee BC, Chen HY, Chian RC, (2009) Effect of a phosphodiesterase type 3 inhibitor in oocyte maturation medium on subsequent mouse embryo development. Fertility and Sterility 91 (5 Suppl): 2037-2042.
26. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, et al. (2004) Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. The Journal of Clinical Investigation 114 (2): 196-205.
27. Nogueira D, Cortvrindt R, Everaerdt B, Smitz J, (2005) Effects of long-term in vitro exposure to phosphodiesterase type-3 inhibitors on follicle and oocyte development. Reproduction (Cambridge, England) 130 (2): 177-186.
28. Liu Y, Shakur Y, Yoshitake M, Kambayashi JJ, (2001) Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovascular Drug Reviews 19 (4): 369-386.
29. Schror K, (2002) The pharmacology of cilostazol. Diabetes, Obesity & Metabolism 4 (Suppl 2): S14-19.
30. Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, et al. (2002) Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy 16 (5): 417-427.
31. Wu SN, Liu SI, Huang MH, (2004) Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells. Endocrinology 145 (3): 1175-1184.
32. Kimura Y, Yanagimachi R, (1995) Intracytoplasmic sperm injection in the mouse. Biology of Reproduction 52 (4): 709-720.